What is the dosage of oxintuzumab/oxintuzumab (Besponsa)?

The dosage of Oxantuzumab/Oxantuzumab (Besponsa) is based on the patient's specific situation and the doctor's prescription. Therefore, patients must follow the advice and guidance of a medical professional before use. However, the following is some general information regarding the dosage of oxinutuzumab/oxinutuzumab for reference:

1.Initial treatment dosage: Generally, the initial treatment dosage of oxinutuzumab is 1.8 mg per square meter of body surface area, once per cycle, as an intravenous injection. Treatment is usually given in one 28-day cycle and may require multiple cycles, depending on the patient's condition and response to treatment.

2Continuing treatment dosage: After initial treatment, patients may need to continue receiving oxinutuzumab/oxinutuzumab to maintain leukemia remission. The dosage and frequency of this phase are usually determined by the doctor based on the patient's condition.

3.Drug management: Olintuzumab/Olintuzumab is administered by intravenous injection, usually by a medical professional in a medical setting. Injections will be administered on a certain schedule, and patients need to follow the doctor's instructions and visit the hospital regularly for treatment during the treatment period.

4.Dose adjustment: During treatment, the doctor may adjust the dosage of oxinutuzumab/oxinutuzumab according to the specific conditions of the patient. This can be determined based on the patient's response to treatment and any side effects that occur. Dosage adjustments help ensure optimal therapeutic effects of the drug and reduce the risk of adverse reactions.

It needs to be emphasized that,Olintuzumab/Olintuzumab dosage is highly individualized and depends on the patient's age, weight, severity of illness, and other factors. Therefore, patients must strictly follow their doctor's recommendations before using oxinuximab and maintain close medical monitoring during treatment. Only a medical professional can determine the dosage and treatment plan that is best for each patient to ensure the medication is safe and effective. Patients should always talk to their doctor if they have any questions or concerns about medication dosage.

Ogaintozumab/Ointozumab has been launched in China, but it is not included in medical insurance. The domestic price is around 60,000 to 70,000 yuan, which is very expensive. Patients can buy it domestically. There are only original drugs available abroad, mainly Pfizer’s original drugs, which cost more than 80,000 yuan.